Janus Kinase Inhibitors Competitive Landscape Insights | Clinical Trials, Latest Approvals, Therapies, Key Companies | Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris

DelveInsight's "Janus Kinase (JAK) Inhibitor Market Size, Target Population, Competitive Landscape and Market Forecast - 2034" report delivers an in-depth understanding of Janus Kinase (JAK) Inhibitor, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.
DelveInsight's "Janus kinase (JAK) inhibitors Competitive landscape, 2023 [https://www.delveinsight.com/report-store/janus-kinase-jak-inhibitors-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report provides comprehensive insights about 40+ companies and 45+ drugs in Janus kinase (JAK) inhibitors Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Recent developments in the Janus Kinase Inhibitors Pipeline Segment:

*
December 2022: Incyte and CMS Aesthetics Collaboration

In December 2022, Incyte and CMS Aesthetics announced a Collaboration and License Agreement to develop and commercialize ruxolitinib cream, a novel formulation of Incyte's selective JAK inhibitor ruxolitinib. This cream is intended for treating autoimmune and inflammatory dermatologic diseases in Greater China and specific countries in Southeast Asia.

*
September 2022: Bristol Myers Squibb's POETYK PSO Trial

In September 2022, Bristol Myers Squibb released two-year results from the POETYK PSO long-term extension (LTE) trial, which demonstrated sustained clinical efficacy of Sotyktu Trademark (deucravacitinib) in adult patients with moderate-to-severe plaque psoriasis. The analysis included patients from the pivotal POETYK PSO-1 trial who transitioned into the LTE trial. After 112 weeks of Sotyktu treatment, the modified non-responder imputation (mNRI) response rates were 82.4% for Psoriasis Area and Severity Index (PASI) 75, 55.2% for PASI 90, and 66.5% for static Physician's Global Assessment (sPGA) 0/1.

*
June 2022: FDA Approval of OLUMIANT Registered (Baricitinib)

In June 2022, Eli Lilly and Incyte announced that the US Food and Drug Administration (FDA) approved OLUMIANT Registered (baricitinib), a once-daily pill, as the first systemic treatment for adults with severe alopecia areata (AA). It is available in 4-mg, 2-mg, and 1-mg tablets.

*
July 2022: AbbVie's Submission for Upadacitinib in Crohn's Disease

In July 2022, AbbVie submitted applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for a new indication of upadacitinib (RINVOQ Registered ). The applications seek approval for using upadacitinib as a treatment for adult patients with moderately to severely active Crohn's disease, with doses of 45 mg (induction dose) and 15 mg and 30 mg (maintenance doses).

*
March 2022: FDA Approval of RINVOQ Registered (Upadacitinib) for Ulcerative Colitis

In March 2022, AbbVie announced the FDA approval of RINVOQ Registered (upadacitinib) for treating adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. This marks the first indication for RINVOQ in gastroenterology, supported by efficacy and safety data from three Phase 3 randomized, double-blind, placebo-controlled clinical studies.

*
January 2022: FDA Approval of RINVOQ Registered (Upadacitinib) for Atopic Dermatitis

In January 2022, AbbVie announced the FDA approval of RINVOQ Registered (upadacitinib) for treating moderate to severe atopic dermatitis in adults and children aged 12 years and older. This approval is for patients whose disease did not respond to previous treatments or is not well controlled with other pills or injections, including biologic medicines, or when the use of other pills or injections is not recommended.

Request for a sample page: https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitors-market [https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitors-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Janus Kinase Inhibitors Overview

Janus kinase (JAK) inhibitors, also known as jakinibs, are small molecules (approximately 400 Da) that can be administered orally. JAKs are phosphotransferases that bind to the intracellular domains of cytokine receptors, transmitting signals to activate immune responses. Cytokines signaling via JAKs include many interleukins, interferons, colony-stimulating factors, and hormone-like cytokines (such as erythropoietin). These cytokine receptors utilize various combinations of the four JAKs: JAK1, JAK2, JAK3, and TYK2.

Janus kinase Inhibitors Mechanism of Action

JAK inhibitors block the JAK-STAT signaling pathway, which is critical for transmitting signals from cytokine receptors on the cell membrane to the nucleus, influencing gene expression. By inhibiting JAKs, these drugs can modulate the immune response and reduce inflammation.

Janus kinase Inhibitors First-Generation JAK Inhibitors

First-generation jakinibs, such as tofacitinib and baricitinib (and oclacitinib for dogs), inhibit more than one JAK and, consequently, a broad range of cytokines. These pan-JAK inhibitors are being explored as therapeutic agents for various autoimmune diseases due to their ability to suppress multiple cytokine signals.

Janus kinase Inhibitors Clinical Applications and Efficacy

JAK inhibitors have proven effective in treating several autoimmune and rheumatic diseases, including rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD). Recent studies have also identified the involvement of the JAK-STAT pathway in the pathogenesis of psoriatic arthritis (PsA), particularly through cytokines related to the interleukin (IL)-12/23 and IL-17 axes.

Janus kinase Inhibitors Adverse Effects

Common adverse effects of JAK inhibitors include:

- Infection

- Anemia

- Neutropenia

- Lymphopenia

- Hyperlipidemia

These effects are expected due to the inhibition of multiple JAKs and cytokines. The infection rates in patients treated with JAK inhibitors are comparable to those observed with other immunosuppressive drugs and biologic agents.

Janus kinase Inhibitors Current and Future Directions

Numerous cytokines signal via the JAK-STAT pathway, which is crucial for the immune response, host defense, and inflammation. Blocking JAK kinase isoforms has opened a new chapter in treating various cancers and autoimmune diseases. Clinical trials are ongoing to evaluate the efficacy of several JAK inhibitors in conditions ranging from myelofibrosis to autoimmune diseases like psoriasis. The future may see the development of additional JAK inhibitors effective across multiple disorders.

The inhibition of the JAK-STAT pathway represents a significant advancement in treating autoimmune and inflammatory diseases. With ongoing research and clinical trials, JAK inhibitors continue to show promise for broader therapeutic applications, potentially transforming the management of various immune-mediated and oncologic conditions.

Janus kinase Inhibitors Pipeline Analysis

The report provides insights into:

The report provides detailed insights into the emerging Janus kinase Inhibitors in the market and the aggregate therapies developed by major pharma companies.

*
It accesses the different Janus kinase Inhibitors therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development.

*
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Janus kinase Inhibitors Market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Analysis of Emerging Janus kinase Inhibitors by Phases

The report covers the emerging products under different phases of clinical development like -

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

Learn How the Ongoing Clinical & Commercial Activities will Affect the Janus kinase Inhibitors Therapeutic Segment @ https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitors-market [https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitors-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Key Companies in the Janus kinase Inhibitors Therapeutics Market [https://www.delveinsight.com/report-store/janus-kinase-jak-inhibitors-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] Include: Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co.,MaxiNovel Pharmaceuticals, and others.

Janus kinase Inhibitors Covered and Analyzed in the Report Include:

*
ATI-2138: Aclaris Therapeutics

*
CPL409116: Celon Pharma

*
Filgotinib: Galapagos

*
Golidocitinib: Dizal Pharmaceutical

*
Itacitinib: Incyte Corporation

*
Ivarmacitinib: Arcutis Biotherapeutics/Reistone Biopharma

*
Momelotinib: Sierra Oncology

*
Nezulcitinib: Theravance Biopharma

*
RINVOQ: AbbVie

*
Ritlecitinib: Pfizer

*
Ruxolitinib: Incyte Corporation/Novartis

*
TD 5202: Theravance Biopharma

Table of Contents

1. Report Introduction

2. Executive Summary

3. Janus kinase Inhibitors Current Treatment Patterns

4. Janus kinase Inhibitors - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Janus kinase Inhibitors Late Stage Products (Phase-III)

7. Janus kinase Inhibitors Mid-Stage Products (Phase-II)

8. Janus kinase Inhibitors Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Janus kinase Inhibitors Discontinued Products

13. Janus kinase Inhibitors Product Profiles

14. Key Companies in the Janus kinase Inhibitors Market

15. Key Products in the Janus kinase Inhibitors Therapeutics Segment

16. Dormant and Discontinued Products

17. Janus kinase Inhibitors Unmet Needs

18. Janus kinase Inhibitors Future Perspectives

19. Janus kinase Inhibitors Analyst Review

20. Appendix

21. Report Methodology

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=janus-kinase-inhibitors-competitive-landscape-insights-clinical-trials-latest-approvals-therapies-key-companies-pfizer-sierra-oncology-theravance-biopharma-dizal-pharmaceutical-aclaris]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.